The HuFriedyGroup has announced that its chief executive officer, Andy Xilas, will be stepping down and that he will be succeeded by veteran MedTech executive Robert Woolley, according to a September 2, 2025, press release from the company.
Xilas, who has more than 35 years of experience at HuFriedyGroup, was appointed as CEO in January 2021. Among other achievements, he guided the organization through a pivotal period of transformation, innovation, and growth, including leading it through its divestiture from STERIS plc to become a standalone global dental products company. Xilas's leadership was instrumental in helping the company to expand its global footprint, acquire and integrate new dental brands, and strengthen its position as a trusted partner to dental professionals. Now, as a senior advisor to the board, Xilas will continue to serve the organization.
With 2 decades of global medical device and dental experience, incoming CEO Robert Woolley brings deep industry knowledge, global expertise, and a track record of achieving growth to HuFriedyGroup, which will be essential in the company’s next phase of accelerated growth and innovation. He holds a Bachelor of Science degree in mechanical engineering from Brigham Young University and an MBA from Harvard University. Woolley, who most recently served as group vice president of hearing instruments at Sonova Group, previously held key executive roles at Straumann Group, including serving as the company’s executive vice president for North America and Western Europe. He has also held senior positions at Medtronic, Trivascular, and Stryker, where he earned recognition for driving commercial excellence, portfolio innovation, and operational performance across the U.S. and European markets.
